{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T21:20:57Z","timestamp":1792099257259,"version":"4.4.0"},"reference-count":187,"publisher":"MDPI AG","issue":"13","license":[{"start":{"date-parts":[[2023,6,29]],"date-time":"2023-06-29T00:00:00Z","timestamp":1687996800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>This review article offers an outlook on the use of opioids as therapeutics for treating several diseases, including cancer and non-cancer pain, and focuses the analysis on the opportunity to target opioid receptors for treating opioid use disorder (OUD), drug withdrawal, and addiction. Unfortunately, as has been well established, the use of opioids presents a plethora of side effects, such as tolerance and physical and physiological dependence. Accordingly, considering the great pharmacological potential in targeting opioid receptors, the identification of opioid receptor ligands devoid of most of the adverse effects exhibited by current therapeutic agents is highly necessary. To this end, herein, we analyze some interesting molecules that could potentially be useful for treating OUD, with an in-depth analysis regarding in vivo studies and clinical trials.<\/jats:p>","DOI":"10.3390\/ijms241310888","type":"journal-article","created":{"date-parts":[[2023,6,30]],"date-time":"2023-06-30T00:43:30Z","timestamp":1688085810000},"page":"10888","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":18,"title":["Targeting Opioid Receptors in Addiction and Drug Withdrawal: Where Are We Going?"],"prefix":"10.3390","volume":"24","author":[{"given":"Rita","family":"Tabanelli","sequence":"first","affiliation":[{"name":"Department of Pharmacy, University of Pisa, Via Bonanno 6, 56126 Pisa, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9375-6242","authenticated-orcid":false,"given":"Simone","family":"Brogi","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, University of Pisa, Via Bonanno 6, 56126 Pisa, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincenzo","family":"Calderone","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, University of Pisa, Via Bonanno 6, 56126 Pisa, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2023,6,29]]},"reference":[{"key":"ref_1","unstructured":"Azadfard, M., Huecker, M.R., and Leaming, J.M. (2023, January 10). Opioid Addiction [Updated 1 January 2023], Available online: https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK448203\/."},{"key":"ref_2","unstructured":"(2023, January 10). Available online: https:\/\/www.cdc.gov\/opioids\/healthcare-professionals\/prescribing\/opioid-use-disorder.html."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1038\/s41572-019-0137-5","article-title":"Opioid use disorder","volume":"6","author":"Strang","year":"2020","journal-title":"Nat. Rev. Dis. Prim."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"268","DOI":"10.7326\/M16-2149","article-title":"Primary Care-Based Models for the Treatment of Opioid Use Disorder: A Scoping Review","volume":"166","author":"Korthuis","year":"2017","journal-title":"Ann. Intern. Med."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1007\/s11920-020-01149-0","article-title":"Identification and Management of Opioid Use Disorder in Primary Care: An Update","volume":"22","author":"Donroe","year":"2020","journal-title":"Curr. Psychiatry Rep."},{"key":"ref_6","doi-asserted-by":"crossref","unstructured":"Hoffman, K.A., Ponce Terashima, J., and McCarty, D. (2019). Opioid use disorder and treatment: Challenges and opportunities. BMC Health Serv. Res., 19.","DOI":"10.1186\/s12913-019-4751-4"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"2448","DOI":"10.1001\/jama.2018.18472","article-title":"Opioids for Chronic Noncancer Pain: A Systematic Review and Meta-analysis","volume":"320","author":"Busse","year":"2018","journal-title":"J. Am. Med. Assoc."},{"key":"ref_8","first-page":"CD012592","article-title":"Opioids for cancer pain\u2014An overview of Cochrane reviews","volume":"7","author":"Wiffen","year":"2017","journal-title":"Cochrane Database Syst. Rev."},{"key":"ref_9","first-page":"2408","article-title":"Opioids in people with cancer-related pain","volume":"2008","author":"Quigley","year":"2008","journal-title":"BMJ Clin. Evid."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"E659","DOI":"10.1503\/cmaj.170363","article-title":"Guideline for opioid therapy and chronic noncancer pain","volume":"189","author":"Busse","year":"2017","journal-title":"Can. Med. Assoc. J."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"751","DOI":"10.2217\/pmt-2022-0017","article-title":"Management of chronic non-cancer pain: A framework","volume":"12","author":"Nadeau","year":"2022","journal-title":"Pain Manag."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1016\/j.neubiorev.2020.12.015","article-title":"Analgesic opioid use disorders in patients with chronic non-cancer pain: A holistic approach for tailored management","volume":"121","author":"Bertin","year":"2021","journal-title":"Neurosci. Biobehav. Rev."},{"key":"ref_13","doi-asserted-by":"crossref","unstructured":"Graven-Nielsen, C.S., Knoph, C.S., Okdahl, T., Hoyer, K.L., Krogh, K., Hellstrom, P.M., and Drewes, A.M. (2023). Opioids in the Treatment of Chronic Idiopathic Diarrhea in Humans-A Systematic Review and Treatment Guideline. J. Clin. Med., 12.","DOI":"10.3390\/jcm12072488"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/j.cgh.2016.07.028","article-title":"Chronic Diarrhea: Diagnosis and Management","volume":"15","author":"Schiller","year":"2017","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1111\/j.1365-2036.1987.tb00617.x","article-title":"Review: Loperamide\u2014A potent antidiarrhoeal drug with actions along the alimentary tract","volume":"1","author":"Ruppin","year":"1987","journal-title":"Aliment. Pharmacol. Ther."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1136\/thx.2003.013490","article-title":"Cough. 7: Current and future drugs for the treatment of chronic cough","volume":"59","author":"Belvisi","year":"2004","journal-title":"Thorax"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"S239","DOI":"10.37765\/ajmc.2020.88515","article-title":"Updates in treatment of adults with chronic cough","volume":"26","author":"On","year":"2020","journal-title":"Am. J. Manag. Care"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1080\/17512433.2021.1903316","article-title":"Opioids for chronic low back pain management: A Bayesian network meta-analysis","volume":"14","author":"Migliorini","year":"2021","journal-title":"Expert. Rev. Clin. Pharmacol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1002\/ejp.1519","article-title":"Opioids for chronic low back pain: An updated systematic review and meta-analysis of efficacy, tolerability and safety in randomized placebo-controlled studies of at least 4 weeks of double-blind duration","volume":"24","author":"Petzke","year":"2020","journal-title":"Eur. J. Pain"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1177\/2040622315608648","article-title":"The diagnosis and treatment of chronic migraine: The case for daily scheduled opioid treatment in chronic headache","volume":"6","author":"Derakhshan","year":"2015","journal-title":"Ther. Adv. Chronic. Dis."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1111\/j.1526-4610.2010.01728.x","article-title":"Opiate and opioid (\u201cnarcotic\u201d) therapy for acute migraine headache","volume":"50","author":"Rothrock","year":"2010","journal-title":"Headache"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1016\/j.bja.2021.02.030","article-title":"Surgery and opioids: Evidence-based expert consensus guidelines on the perioperative use of opioids in the United Kingdom","volume":"126","author":"Srivastava","year":"2021","journal-title":"Br. J. Anaesth."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1001\/jamasurg.2020.5045","article-title":"Guidelines for Opioid Prescribing in Children and Adolescents After Surgery: An Expert Panel Opinion","volume":"156","author":"Kirkpatrick","year":"2021","journal-title":"JAMA Surg."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"2245","DOI":"10.1016\/S0140-6736(22)00777-2","article-title":"Opioid-free analgesia after surgery","volume":"399","author":"Myles","year":"2022","journal-title":"Lancet"},{"key":"ref_25","first-page":"304","article-title":"Prescription Opioid and Benzodiazepine Use After Road Traffic Injury","volume":"17","author":"Collie","year":"2016","journal-title":"Pain Med."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1002\/psb.1755","article-title":"Opioid use in palliative care: New developments and guidelines","volume":"30","author":"Gishen","year":"2019","journal-title":"Prescriber"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1136\/bmjspcare-2021-003178","article-title":"Opioid safety recommendations in adult palliative medicine: A North American Delphi expert consensus","volume":"12","author":"Lau","year":"2022","journal-title":"BMJ Support. Palliat. Care"},{"key":"ref_28","first-page":"348","article-title":"The role of palliative care at the end of life","volume":"11","author":"Rome","year":"2011","journal-title":"Ochsner. J."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"S105","DOI":"10.36076\/ppj.2008\/11\/S105","article-title":"Opioid complications and side effects","volume":"11","author":"Benyamin","year":"2008","journal-title":"Pain Physician"},{"key":"ref_30","doi-asserted-by":"crossref","unstructured":"(2018). Adverse effects of opioids for non-cancer pain. Drug Ther. Bull., 56, 15\u201316.","DOI":"10.1136\/dtb.2018.2.0583"},{"key":"ref_31","first-page":"CD012509","article-title":"Adverse events associated with medium- and long-term use of opioids for chronic non-cancer pain: An overview of Cochrane Reviews","volume":"10","author":"Els","year":"2017","journal-title":"Cochrane Database Syst. Rev."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"3197","DOI":"10.2174\/1381612825666190717152226","article-title":"Opioid Analgesics Adverse Effects: The Other Side of the Coin","volume":"25","author":"Mercadante","year":"2019","journal-title":"Curr. Pharm. Des."},{"key":"ref_33","doi-asserted-by":"crossref","unstructured":"Paul, A.K., Smith, C.M., Rahmatullah, M., Nissapatorn, V., Wilairatana, P., Spetea, M., Gueven, N., and Dietis, N. (2021). Opioid Analgesia and Opioid-Induced Adverse Effects: A Review. Pharmaceuticals, 14.","DOI":"10.3390\/ph14111091"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1016\/j.jpainsymman.2019.02.009","article-title":"The Burden of Opioid Adverse Events and the Influence on Cancer Patients\u2019 Symptomatology","volume":"57","author":"Corli","year":"2019","journal-title":"J. Pain Symptom Manag."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"200","DOI":"10.2165\/00002018-199207030-00005","article-title":"Adverse effects of systemic opioid analgesics","volume":"7","author":"Schug","year":"1992","journal-title":"Drug Saf."},{"key":"ref_36","first-page":"15","article-title":"Adverse Effects of Opioids on the Central Nervous Systems of Palliative Care Patients","volume":"21","author":"MacLeod","year":"2009","journal-title":"J. Pain Palliat. Care Pharmacother."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1007\/s40122-019-00135-6","article-title":"Stopping or Decreasing Opioid Therapy in Patients on Chronic Opioid Therapy","volume":"8","author":"Pergolizzi","year":"2019","journal-title":"Pain Ther."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1177\/1403494818779955","article-title":"Mortality, morbidity and follow-up after acute poisoning by substances of abuse: A prospective observational cohort study","volume":"47","author":"Vallersnes","year":"2019","journal-title":"Scand. J. Public Health"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1111\/ajad.12862","article-title":"Review article: Effective management of opioid withdrawal symptoms: A gateway to opioid dependence treatment","volume":"28","author":"Kosten","year":"2019","journal-title":"Am. J. Addict."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1111\/jcpt.13114","article-title":"Opioid withdrawal symptoms, a consequence of chronic opioid use and opioid use disorder: Current understanding and approaches to management","volume":"45","author":"Pergolizzi","year":"2020","journal-title":"J. Clin. Pharm. Ther."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1016\/S2215-0366(16)00104-8","article-title":"Neurobiology of addiction: A neurocircuitry analysis","volume":"3","author":"Koob","year":"2016","journal-title":"Lancet Psychiatry"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1016\/j.jpain.2012.03.009","article-title":"The economic costs of pain in the United States","volume":"13","author":"Gaskin","year":"2012","journal-title":"J. Pain"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"108350","DOI":"10.1016\/j.drugalcdep.2020.108350","article-title":"The economic burden of opioid use disorder and fatal opioid overdose in the United States, 2017","volume":"218","author":"Florence","year":"2021","journal-title":"Drug Alcohol. Depend."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"e191532","DOI":"10.1001\/jamanetworkopen.2019.1532","article-title":"The Cost of Pain","volume":"2","author":"Smith","year":"2019","journal-title":"JAMA Netw. Open"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"1388","DOI":"10.3389\/fphar.2018.01388","article-title":"Advances in Achieving Opioid Analgesia Without Side Effects","volume":"9","author":"Machelska","year":"2018","journal-title":"Front. Pharmacol."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1016\/S0165-6147(03)00066-X","article-title":"Historical review: Opioid receptors","volume":"24","author":"Snyder","year":"2003","journal-title":"Trends Pharmacol. Sci."},{"key":"ref_47","first-page":"8","article-title":"Molecular cloning and functional expression of a mu-opioid receptor from rat brain","volume":"44","author":"Chen","year":"1993","journal-title":"Mol. Pharmacol."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"12048","DOI":"10.1073\/pnas.89.24.12048","article-title":"The delta-opioid receptor: Isolation of a cDNA by expression cloning and pharmacological characterization","volume":"89","author":"Kieffer","year":"1992","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1016\/0014-5793(93)80240-U","article-title":"Cloning and expression of a cDNA for the rat kappa-opioid receptor","volume":"329","author":"Minami","year":"1993","journal-title":"FEBS Lett."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1124\/mol.120.119420","article-title":"A Concise Review of Concepts in Opioid Pharmacology up to the Discovery of Endogenous Opioids","volume":"98","author":"Cox","year":"2020","journal-title":"Mol. Pharmacol."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"1014768","DOI":"10.3389\/fnsys.2022.1014768","article-title":"Endogenous opioid systems alterations in pain and opioid use disorder","volume":"16","author":"Higginbotham","year":"2022","journal-title":"Front. Syst. Neurosci."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1038\/nature08144","article-title":"The structure and function of G-protein-coupled receptors","volume":"459","author":"Rosenbaum","year":"2009","journal-title":"Nature"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1097\/ALN.0b013e318238bba6","article-title":"Molecular mechanisms of opioid receptor-dependent signaling and behavior","volume":"115","author":"Bruchas","year":"2011","journal-title":"Anesthesiology"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"255","DOI":"10.3389\/fphar.2014.00255","article-title":"Discovery of GPCR ligands for probing signal transduction pathways","volume":"5","author":"Brogi","year":"2014","journal-title":"Front. Pharmacol."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1016\/j.bbrc.2021.05.002","article-title":"Modulation of glutamatergic synaptic transmission and neuronal excitability in the prelimbic medial prefrontal cortex via delta-opioid receptors in mice","volume":"560","author":"Yamada","year":"2021","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1080\/13556210500123019","article-title":"Constitutive opioid receptor activation: A prerequisite mechanism involved in acute opioid withdrawal","volume":"10","author":"Freye","year":"2005","journal-title":"Addict. Biol."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"S133","DOI":"10.36076\/ppj.2008\/11\/S133","article-title":"Opioid pharmacology","volume":"11","author":"Trescot","year":"2008","journal-title":"Pain Physician"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.1152\/physrev.00005.2009","article-title":"Reward processing by the opioid system in the brain","volume":"89","author":"Becker","year":"2009","journal-title":"Physiol. Rev."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"919773","DOI":"10.3389\/fnmol.2022.919773","article-title":"Opioid Receptor-Mediated Regulation of Neurotransmission in the Brain","volume":"15","author":"Reeves","year":"2022","journal-title":"Front. Mol. Neurosci."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"2904","DOI":"10.3389\/fimmu.2019.02904","article-title":"The Role of Opioid Receptors in Immune System Function","volume":"10","author":"Eisenstein","year":"2019","journal-title":"Front. Immunol."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"1716","DOI":"10.14309\/ajg.0000000000000354","article-title":"Opioid-Induced Foregut Dysfunction","volume":"114","author":"Patel","year":"2019","journal-title":"Am. J. Gastroenterol."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.pneurobio.2009.09.004","article-title":"Modulation of alcohol and nicotine responses through the endogenous opioid system","volume":"90","author":"Drews","year":"2010","journal-title":"Prog. Neurobiol."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"173072","DOI":"10.1016\/j.pbb.2020.173072","article-title":"Progress in opioid reward research: From a canonical two-neuron hypothesis to two neural circuits","volume":"200","author":"Galaj","year":"2021","journal-title":"Pharmacol. Biochem. Behav."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1016\/0166-2236(93)90194-Q","article-title":"Molecular biology of opioid receptors","volume":"16","author":"Reisine","year":"1993","journal-title":"Trends Neurosci."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"1346","DOI":"10.1016\/j.neuron.2014.04.030","article-title":"Separate GABA afferents to dopamine neurons mediate acute action of opioids, development of tolerance, and expression of withdrawal","volume":"82","author":"Matsui","year":"2014","journal-title":"Neuron"},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1208\/s12248-008-9056-1","article-title":"Opioid tolerance development: A pharmacokinetic\/pharmacodynamic perspective","volume":"10","author":"Dumas","year":"2008","journal-title":"AAPS J."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.3892\/etm.2021.10437","article-title":"Molecular mechanisms of opioid tolerance: From opioid receptors to inflammatory mediators (Review)","volume":"22","author":"Zhou","year":"2021","journal-title":"Exp. Ther. Med."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.peptides.2019.01.003","article-title":"Inflammatory mediators of opioid tolerance: Implications for dependency and addiction","volume":"115","author":"Eidson","year":"2019","journal-title":"Peptides"},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1151\/spp021113","article-title":"The neurobiology of opioid dependence: Implications for treatment","volume":"1","author":"Kosten","year":"2002","journal-title":"Sci. Pract. Perspect."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1007\/BF02246097","article-title":"Increase of extracellular dopamine in the medial prefrontal cortex during spontaneous and naloxone-precipitated opiate abstinence","volume":"122","author":"Bassareo","year":"1995","journal-title":"Psychopharmacology"},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1016\/0006-8993(93)90889-U","article-title":"Extraneuronal noradrenaline in the prefrontal cortex of morphine-dependent rats: Tolerance and withdrawal mechanisms","volume":"609","author":"Rossetti","year":"1993","journal-title":"Brain Res."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1016\/S0893-133X(01)00226-3","article-title":"Behavioral expression of opiate withdrawal is altered after prefrontocortical dopamine depletion in rats: Monoaminergic correlates","volume":"25","author":"Espejo","year":"2001","journal-title":"Neuropsychopharmacology"},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1016\/j.neubiorev.2009.02.005","article-title":"The role of glutamate and its receptors in mesocorticolimbic dopaminergic regions in opioid addiction","volume":"33","author":"Guo","year":"2009","journal-title":"Neurosci. Biobehav. Rev."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/S0079-6123(08)63810-8","article-title":"Afferent effects on locus coeruleus in opiate withdrawal","volume":"88","author":"Rasmussen","year":"1991","journal-title":"Prog. Brain Res."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"1850","DOI":"10.1007\/s11064-013-1091-3","article-title":"Suppression of hypothalamic-pituitary-adrenal axis by acute heroin challenge in rats during acute and chronic withdrawal from chronic heroin administration","volume":"38","author":"Zhou","year":"2013","journal-title":"Neurochem. Res."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1038\/s41398-021-01548-8","article-title":"Naloxone precipitated withdrawal increases dopamine release in the dorsal striatum of opioid dependent men","volume":"11","author":"Wang","year":"2021","journal-title":"Transl. Psychiatry"},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"245","DOI":"10.7326\/M15-2771","article-title":"Nonrandomized Intervention Study of Naloxone Coprescription for Primary Care Patients Receiving Long-Term Opioid Therapy for Pain","volume":"165","author":"Coffin","year":"2016","journal-title":"Ann. Intern. Med."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"455","DOI":"10.31887\/DCNS.2007.9.2\/hkleber","article-title":"Pharmacologic treatments for opioid dependence: Detoxification and maintenance options","volume":"9","author":"Kleber","year":"2007","journal-title":"Dialogues Clin. Neurosci."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1093\/bja\/ael051","article-title":"Buprenorphine induces ceiling in respiratory depression but not in analgesia","volume":"96","author":"Dahan","year":"2006","journal-title":"Br. J. Anaesth."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1097\/HRP.0000000000000075","article-title":"Medication-assisted treatment of opioid use disorder: Review of the evidence and future directions","volume":"23","author":"Connery","year":"2015","journal-title":"Harv. Rev. Psychiatry"},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"1947","DOI":"10.1001\/jamainternmed.2014.5302","article-title":"Primary care-based buprenorphine taper vs maintenance therapy for prescription opioid dependence: A randomized clinical trial","volume":"174","author":"Fiellin","year":"2014","journal-title":"JAMA Intern. Med."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1016\/S0140-6736(03)12600-1","article-title":"1-year retention and social function after buprenorphine-assisted relapse prevention treatment for heroin dependence in Sweden: A randomised, placebo-controlled trial","volume":"361","author":"Kakko","year":"2003","journal-title":"Lancet"},{"key":"ref_83","first-page":"CD002207","article-title":"Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence","volume":"6","author":"Mattick","year":"2014","journal-title":"Cochrane Database Syst. Rev."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"85","DOI":"10.3109\/10826084.2015.1089905","article-title":"Buprenorphine Maintenance Treatment of Opiate Dependence: Correlations Between Prescriber Beliefs and Practices","volume":"51","author":"MacDonald","year":"2016","journal-title":"Subst. Use Misuse"},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1111\/j.1749-6632.2000.tb06683.x","article-title":"Methadone-related opioid agonist pharmacotherapy for heroin addiction. History, recent molecular and neurochemical research and future in mainstream medicine","volume":"909","author":"Kreek","year":"2000","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1093\/ajhp\/zxz105","article-title":"Medications for management of opioid use disorder","volume":"76","author":"Koehl","year":"2019","journal-title":"Am. J. Health Syst. Pharm."},{"key":"ref_87","first-page":"CD002209","article-title":"Methadone maintenance therapy versus no opioid replacement therapy for opioid dependence","volume":"2009","author":"Mattick","year":"2009","journal-title":"Cochrane Database Syst. Rev."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1001\/archpsyc.63.1.102","article-title":"A randomized controlled trial of interim methadone maintenance","volume":"63","author":"Schwartz","year":"2006","journal-title":"Arch. Gen. Psychiatry"},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"1506","DOI":"10.1016\/S0140-6736(11)60358-9","article-title":"Injectable extended-release naltrexone for opioid dependence: A double-blind, placebo-controlled, multicentre randomised trial","volume":"377","author":"Krupitsky","year":"2011","journal-title":"Lancet"},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/S0140-6736(17)32812-X","article-title":"Comparative effectiveness of extended-release naltrexone versus buprenorphine-naloxone for opioid relapse prevention (X:BOT): A multicentre, open-label, randomised controlled trial","volume":"391","author":"Lee","year":"2018","journal-title":"Lancet"},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1097\/ADM.0000000000000125","article-title":"Treating Opioid Dependence With Injectable Extended-Release Naltrexone (XR-NTX): Who Will Respond?","volume":"9","author":"Nunes","year":"2015","journal-title":"J. Addict. Med."},{"key":"ref_92","first-page":"CD001333","article-title":"Oral naltrexone maintenance treatment for opioid dependence","volume":"2011","author":"Minozzi","year":"2011","journal-title":"Cochrane Database Syst. Rev."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"1628","DOI":"10.1111\/add.12208","article-title":"Injectable extended-release naltrexone (XR-NTX) for opioid dependence: Long-term safety and effectiveness","volume":"108","author":"Krupitsky","year":"2013","journal-title":"Addiction"},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1007\/s40263-013-0110-x","article-title":"Extended-release intramuscular naltrexone (VIVITROL(R)): A review of its use in the prevention of relapse to opioid dependence in detoxified patients","volume":"27","author":"Syed","year":"2013","journal-title":"CNS Drugs"},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1080\/08897077.2015.1010031","article-title":"Cost-Effectiveness of Injectable Extended-Release Naltrexone Compared with Methadone Maintenance and Buprenorphine Maintenance Treatment for Opioid Dependence","volume":"36","author":"Jackson","year":"2023","journal-title":"Subst. Abus."},{"key":"ref_96","unstructured":"(2023, June 10). Available online: https:\/\/nida.nih.gov\/publications\/research-reports\/medications-to-treat-opioid-addiction\/efficacy-medications-opioid-use-disorder."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"j1550","DOI":"10.1136\/bmj.j1550","article-title":"Mortality risk during and after opioid substitution treatment: Systematic review and meta-analysis of cohort studies","volume":"357","author":"Sordo","year":"2017","journal-title":"Br. Med. J."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1080\/10550887.2013.824333","article-title":"Comparison of QTc interval prolongation for patients in methadone versus buprenorphine maintenance treatment: A 5-year follow-up","volume":"32","author":"Fareed","year":"2013","journal-title":"J. Addict. Dis."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"231","DOI":"10.9740\/mhc.2021.07.231","article-title":"Evaluation of drug-drug interactions in hospitalized patients on medications for OUD","volume":"11","author":"Berger","year":"2021","journal-title":"Ment. Health Clin."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1056\/NEJMra1604339","article-title":"Treatment of Opioid-Use Disorders","volume":"375","author":"Schuckit","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"1760","DOI":"10.1016\/S0140-6736(18)33078-2","article-title":"Management of opioid use disorder in the USA: Present status and future directions","volume":"393","author":"Blanco","year":"2019","journal-title":"Lancet"},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1001\/jamapsychiatry.2018.3126","article-title":"Prevention and Treatment of Opioid Misuse and Addiction: A Review","volume":"76","author":"Volkow","year":"2019","journal-title":"JAMA Psychiatry"},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.cct.2016.12.003","article-title":"Effectiveness of adjunctive, personalised psychosocial intervention for non-response to opioid agonist treatment: Study protocol for a pragmatic randomised controlled trial","volume":"53","author":"Marsden","year":"2017","journal-title":"Contemp. Clin. Trials"},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1016\/j.psc.2010.04.012","article-title":"Cognitive behavioral therapy for substance use disorders","volume":"33","author":"McHugh","year":"2010","journal-title":"Psychiatr Clin. N. Am."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"592","DOI":"10.3389\/fpsyt.2019.00592","article-title":"Craving in Opioid Use Disorder: From Neurobiology to Clinical Practice","volume":"10","author":"Kakko","year":"2019","journal-title":"Front. Psychiatry"},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1186\/s13063-023-07102-9","article-title":"Use of a sequential multiple assignment randomized trial to test contingency management and an integrated behavioral economic and mindfulness intervention for buprenorphine-naloxone medication adherence for opioid use disorder","volume":"24","author":"Peter","year":"2023","journal-title":"Trials"},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1037\/0022-006X.70.2.398","article-title":"Low-cost contingency management for treating cocaine- and opioid-abusing methadone patients","volume":"70","author":"Petry","year":"2002","journal-title":"J. Consult. Clin. Psychol."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"1546","DOI":"10.1111\/j.1360-0443.2006.01581.x","article-title":"Contingency management for treatment of substance use disorders: A meta-analysis","volume":"101","author":"Prendergast","year":"2006","journal-title":"Addiction"},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1037\/0022-006X.71.2.320","article-title":"Treatment responsivity of cocaine-dependent patients with antisocial personality disorder to cognitive-behavioral and contingency management interventions","volume":"71","author":"Messina","year":"2003","journal-title":"J. Consult. Clin. Psychol."},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/S0376-8716(02)00023-6","article-title":"Abstinence reinforcement maintenance contingency and one-year follow-up","volume":"67","author":"Preston","year":"2002","journal-title":"Drug Alcohol. Depend."},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1111\/papt.12080","article-title":"Cognitive-behavioural therapy for heroin and cocaine use: Ecological momentary assessment of homework simplification and compliance","volume":"89","author":"Whitaker","year":"2016","journal-title":"Psychol. Psychother"},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1176\/appi.ajp.2007.06111851","article-title":"A meta-analytic review of psychosocial interventions for substance use disorders","volume":"165","author":"Dutra","year":"2008","journal-title":"Am. J. Psychiatry"},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1080\/08897070903250084","article-title":"Mindfulness-based relapse prevention for substance use disorders: A pilot efficacy trial","volume":"30","author":"Bowen","year":"2009","journal-title":"Subst. Abus."},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.jsat.2019.05.013","article-title":"A pilot study of mindful body awareness training as an adjunct to office-based medication treatment of opioid use disorder","volume":"108","author":"Price","year":"2020","journal-title":"J. Subst. Abus. Treat"},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"106393","DOI":"10.1016\/j.cct.2021.106393","article-title":"Efficacy of mindfulness-based relapse prevention in veterans with substance use disorders: Design and methodology of a randomized clinical trial","volume":"105","author":"Brady","year":"2021","journal-title":"Contemp. Clin. Trials"},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.drugalcdep.2019.07.007","article-title":"Mindfulness-Oriented Recovery Enhancement reduces opioid craving among individuals with opioid use disorder and chronic pain in medication assisted treatment: Ecological momentary assessments from a stage 1 randomized controlled trial","volume":"203","author":"Garland","year":"2019","journal-title":"Drug Alcohol. Depend."},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"2155","DOI":"10.1111\/add.13920","article-title":"A pilot randomized clinical trial testing integrated 12-Step facilitation (iTSF) treatment for adolescent substance use disorder","volume":"112","author":"Kelly","year":"2017","journal-title":"Addiction"},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"102","DOI":"10.5694\/mja2.51623","article-title":"Review of management priorities for invasive infections in people who inject drugs: Highlighting the need for patient-centred multidisciplinary care","volume":"217","author":"Attwood","year":"2022","journal-title":"Med. J. Aust."},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1016\/j.amepre.2021.04.017","article-title":"Supervised Injection Facilities as Harm Reduction: A Systematic Review","volume":"61","author":"Levengood","year":"2021","journal-title":"Am. J. Prev. Med."},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1080\/02791072.2022.2028203","article-title":"A Systematized Review of Drug-checking and Related Considerations for Implementation as A Harm Reduction Intervention","volume":"55","author":"Giulini","year":"2023","journal-title":"J. Psychoact. Drugs"},{"key":"ref_121","doi-asserted-by":"crossref","unstructured":"Lloyd-Smith, E., Wood, E., Zhang, R., Tyndall, M.W., Sheps, S., Montaner, J.S., and Kerr, T. (2010). Determinants of hospitalization for a cutaneous injection-related infection among injection drug users: A cohort study. BMC Public Health, 10.","DOI":"10.1186\/1471-2458-10-327"},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1080\/08897077.2018.1485130","article-title":"Ambulance-attended opioid overdoses: An examination into overdose locations and the role of a safe injection facility","volume":"40","author":"Skulberg","year":"2019","journal-title":"Subst. Abus."},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.1016\/S0140-6736(10)62353-7","article-title":"Reduction in overdose mortality after the opening of North America\u2019s first medically supervised safer injecting facility: A retrospective population-based study","volume":"377","author":"Marshall","year":"2011","journal-title":"Lancet"},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1177\/0022042617727513","article-title":"Highs and Lows: An Interrupted Time-Series Evaluation of the Impact of North America\u2019s Only Supervised Injection Facility on Crime","volume":"48","author":"Myer","year":"2017","journal-title":"J. Drug Issues"},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1111\/j.1360-0443.2009.02837.x","article-title":"The impact of a supervised injecting facility on ambulance call-outs in Sydney, Australia","volume":"105","author":"Salmon","year":"2010","journal-title":"Addiction"},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1093\/pubmed\/fdl090","article-title":"Changes in injecting practices associated with the use of a medically supervised safer injection facility","volume":"29","author":"Stoltz","year":"2007","journal-title":"J. Public Health"},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"120094","DOI":"10.1016\/j.jns.2021.120094","article-title":"Looking beyond the opioid receptor: A desperate need for new treatments for opioid use disorder","volume":"432","author":"Lee","year":"2022","journal-title":"J. Neurol. Sci."},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"8381","DOI":"10.1021\/acs.jmedchem.6b00748","article-title":"Mitragynine\/Corynantheidine Pseudoindoxyls As Opioid Analgesics with Mu Agonism and Delta Antagonism, Which Do Not Recruit beta-Arrestin-2","volume":"59","author":"Varadi","year":"2016","journal-title":"J. Med. Chem."},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"2540","DOI":"10.1111\/add.15818","article-title":"Clinical Management of Opioid Withdrawal","volume":"117","author":"Lu","year":"2022","journal-title":"Addiction"},{"key":"ref_130","doi-asserted-by":"crossref","unstructured":"Jordan, C.G., Kennalley, A.L., Roberts, A.L., Nemes, K.M., Dolma, T., and Piper, B.J. (2022). The Potential of Methocinnamox as a Future Treatment for Opioid Use Disorder: A Narrative Review. Pharmacy, 10.","DOI":"10.20944\/preprints202201.0453.v1"},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"1829","DOI":"10.1016\/j.pain.2014.06.011","article-title":"Biased agonism of the mu-opioid receptor by TRV130 increases analgesia and reduces on-target adverse effects versus morphine: A randomized, double-blind, placebo-controlled, crossover study in healthy volunteers","volume":"155","author":"Soergel","year":"2014","journal-title":"Pain"},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1124\/jpet.112.201616","article-title":"A G protein-biased ligand at the mu-opioid receptor is potently analgesic with reduced gastrointestinal and respiratory dysfunction compared with morphine","volume":"344","author":"DeWire","year":"2013","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"109702","DOI":"10.1016\/j.drugalcdep.2022.109702","article-title":"Alleviation of opioid withdrawal by cannabis and delta-9-tetrahydrocannabinol: A systematic review of observational and experimental human studies","volume":"241","author":"Bahji","year":"2022","journal-title":"Drug Alcohol. Depend."},{"key":"ref_134","doi-asserted-by":"crossref","unstructured":"Wang, S.C., Chen, Y.C., Lee, C.H., and Cheng, C.M. (2019). Opioid Addiction, Genetic Susceptibility, and Medical Treatments: A Review. Int. J. Mol. Sci., 20.","DOI":"10.3390\/ijms20174294"},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1007\/s40473-017-0135-4","article-title":"Developing Repetitive Transcranial Magnetic Stimulation (rTMS) as a Treatment Tool for Cocaine Use Disorder: A Series of Six Translational Studies","volume":"4","author":"Hanlon","year":"2017","journal-title":"Curr. Behav. Neurosci. Rep."},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1002\/da.23004","article-title":"A systematic review and meta-analysis on the effects of transcranial direct current stimulation in depressive episodes","volume":"37","author":"Razza","year":"2020","journal-title":"Depress. Anxiety"},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"1857","DOI":"10.2741\/3347","article-title":"Neuropsychology of deep brain stimulation in neurology and psychiatry","volume":"14","author":"Troster","year":"2009","journal-title":"Front. Biosci."},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1016\/j.brs.2015.11.003","article-title":"Transcutaneous Vagus Nerve Stimulation (tVNS) for Treatment of Drug-Resistant Epilepsy: A Randomized, Double-Blind Clinical Trial (cMPsE02)","volume":"9","author":"Bauer","year":"2016","journal-title":"Brain Stimul."},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"1412","DOI":"10.1001\/jamaneurol.2017.3098","article-title":"Safety and Efficacy of Focused Ultrasound Thalamotomy for Patients With Medication-Refractory, Tremor-Dominant Parkinson Disease: A Randomized Clinical Trial","volume":"74","author":"Bond","year":"2017","journal-title":"JAMA Neurol."},{"key":"ref_140","doi-asserted-by":"crossref","first-page":"117149","DOI":"10.1016\/j.jns.2020.117149","article-title":"Transcranial magnetic stimulation, deep brain stimulation, and other forms of neuromodulation for substance use disorders: Review of modalities and implications for treatment","volume":"418","author":"Mahoney","year":"2020","journal-title":"J. Neurol. Sci."},{"key":"ref_141","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1016\/j.pnpbp.2015.03.002","article-title":"Classic hallucinogens in the treatment of addictions","volume":"64","author":"Bogenschutz","year":"2016","journal-title":"Prog. Neuropsychopharmacol. Biol. Psychiatry"},{"key":"ref_142","doi-asserted-by":"crossref","first-page":"2535","DOI":"10.1007\/s00432-021-03670-y","article-title":"Cytoplasmic LXR expression is an independent marker of poor prognosis for patients with early stage primary breast cancer","volume":"147","author":"Shao","year":"2021","journal-title":"J. Cancer Res. Clin. Oncol."},{"key":"ref_143","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1007\/s00406-021-01267-7","article-title":"Effects of ayahuasca and its alkaloids on substance use disorders: An updated (2016\u20132020) systematic review of preclinical and human studies","volume":"272","author":"Rodrigues","year":"2022","journal-title":"Eur. Arch. Psychiatry Clin. Neurosci."},{"key":"ref_144","doi-asserted-by":"crossref","first-page":"e12424","DOI":"10.1111\/gbb.12424","article-title":"MicroRNAs regulate synaptic plasticity underlying drug addiction","volume":"17","author":"Smith","year":"2018","journal-title":"Genes Brain Behav."},{"key":"ref_145","doi-asserted-by":"crossref","first-page":"882491","DOI":"10.3389\/fpsyt.2022.882491","article-title":"Current Trends and Perspectives in the Immune Therapy for Substance Use Disorders","volume":"13","author":"Vasiliu","year":"2022","journal-title":"Front. Psychiatry"},{"key":"ref_146","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1124\/pr.117.013904","article-title":"Conjugate Vaccine Immunotherapy for Substance Use Disorder","volume":"69","author":"Bremer","year":"2017","journal-title":"Pharmacol. Rev."},{"key":"ref_147","doi-asserted-by":"crossref","first-page":"e00887","DOI":"10.1002\/prp2.887","article-title":"Long-term antagonism and allosteric regulation of mu opioid receptors by the novel ligand, methocinnamox","volume":"9","author":"Zamora","year":"2021","journal-title":"Pharmacol. Res. Perspect."},{"key":"ref_148","doi-asserted-by":"crossref","first-page":"1963","DOI":"10.1038\/s41386-020-0717-9","article-title":"The lasting impact of methocinnamox on opioid self-administration","volume":"45","author":"Townsend","year":"2020","journal-title":"Neuropsychopharmacology"},{"key":"ref_149","first-page":"933","article-title":"Methocinnamox is a potent, long-lasting, and selective antagonist of morphine-mediated antinociception in the mouse: Comparison with clocinnamox, beta-funaltrexamine, and beta-chlornaltrexamine","volume":"294","author":"Broadbear","year":"2000","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"ref_150","doi-asserted-by":"crossref","first-page":"1986","DOI":"10.1038\/s41386-020-0698-8","article-title":"Effects of acute and repeated treatment with methocinnamox, a mu opioid receptor antagonist, on fentanyl self-administration in rhesus monkeys","volume":"45","author":"Maguire","year":"2020","journal-title":"Neuropsychopharmacology"},{"key":"ref_151","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1124\/jpet.120.000387","article-title":"Methocinnamox Reverses and Prevents Fentanyl-Induced Ventilatory Depression in Rats","volume":"377","author":"Jimenez","year":"2021","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"ref_152","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1124\/jpet.118.253286","article-title":"Reversal and Prevention of the Respiratory-Depressant Effects of Heroin by the Novel mu-Opioid Receptor Antagonist Methocinnamox in Rhesus Monkeys","volume":"368","author":"Gerak","year":"2019","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"ref_153","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1124\/jpet.118.252353","article-title":"Long-Lasting Effects of Methocinnamox on Opioid Self-Administration in Rhesus Monkeys","volume":"368","author":"Maguire","year":"2019","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"ref_154","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.drugalcdep.2019.05.005","article-title":"Kratom as a substitute for opioids: Results from an online survey","volume":"202","author":"Coe","year":"2019","journal-title":"Drug Alcohol. Depend."},{"key":"ref_155","doi-asserted-by":"crossref","first-page":"107849","DOI":"10.1016\/j.drugalcdep.2020.107849","article-title":"Kratom (Mitragyna speciosa): User demographics, use patterns, and implications for the opioid epidemic","volume":"208","author":"Cox","year":"2020","journal-title":"Drug Alcohol. Depend."},{"key":"ref_156","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.drugalcdep.2017.03.007","article-title":"Patterns of Kratom use and health impact in the US-Results from an online survey","volume":"176","author":"Grundmann","year":"2017","journal-title":"Drug Alcohol. Depend."},{"key":"ref_157","doi-asserted-by":"crossref","first-page":"23","DOI":"10.2147\/SAR.S164261","article-title":"Current perspectives on the impact of Kratom use","volume":"10","author":"Veltri","year":"2019","journal-title":"Subst. Abus. Rehabil."},{"key":"ref_158","unstructured":"Drug Enforcement Administration (2017). Kratom (Mitragynine speciose korth) (Street Names: Thang, Kakuam, Thom, Ketum, Biak). Unites States Department of Justice, Drug Enforcement Administration; 2013; Drug Enforcement Administration, Drugs of Abuse. A DEA Resource Guide."},{"key":"ref_159","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1016\/j.neuropharm.2017.08.026","article-title":"The medicinal chemistry and neuropharmacology of kratom: A preliminary discussion of a promising medicinal plant and analysis of its potential for abuse","volume":"134","author":"Kruegel","year":"2018","journal-title":"Neuropharmacology"},{"key":"ref_160","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1248\/cpb.52.916","article-title":"Chemistry and pharmacology of analgesic indole alkaloids from the rubiaceous plant, Mitragyna speciosa","volume":"52","author":"Takayama","year":"2004","journal-title":"Chem. Pharm. Bull."},{"key":"ref_161","doi-asserted-by":"crossref","first-page":"6754","DOI":"10.1021\/jacs.6b00360","article-title":"Synthetic and Receptor Signaling Explorations of the Mitragyna Alkaloids: Mitragynine as an Atypical Molecular Framework for Opioid Receptor Modulators","volume":"138","author":"Kruegel","year":"2016","journal-title":"J. Am. Chem. Soc."},{"key":"ref_162","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1111\/adb.12639","article-title":"Abuse liability and therapeutic potential of the Mitragyna speciosa (kratom) alkaloids mitragynine and 7-hydroxymitragynine","volume":"24","author":"Hemby","year":"2019","journal-title":"Addict. Biol."},{"key":"ref_163","doi-asserted-by":"crossref","first-page":"2823","DOI":"10.1007\/s00213-018-4974-9","article-title":"Abuse liability of mitragynine assessed with a self-administration procedure in rats","volume":"235","author":"Yue","year":"2018","journal-title":"Psychopharmacology"},{"key":"ref_164","first-page":"2421","article-title":"Pharmacokinetics of mitragynine in man","volume":"9","author":"Trakulsrichai","year":"2015","journal-title":"Drug Des. Dev. Ther."},{"key":"ref_165","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1007\/s00213-017-4813-4","article-title":"The abuse potential of kratom according the 8 factors of the controlled substances act: Implications for regulation and research","volume":"235","author":"Henningfield","year":"2018","journal-title":"Psychopharmacology"},{"key":"ref_166","doi-asserted-by":"crossref","first-page":"875","DOI":"10.2147\/DDDT.S372612","article-title":"Oliceridine for the Management of Moderate to Severe Acute Postoperative Pain: A Narrative Review","volume":"17","author":"Daksla","year":"2023","journal-title":"Drug Des. Dev. Ther."},{"key":"ref_167","doi-asserted-by":"crossref","first-page":"69","DOI":"10.4103\/sja.sja_510_21","article-title":"Oliceridine-Opioid of the 21(st) Century","volume":"16","author":"Goudra","year":"2022","journal-title":"Saudi. J. Anaesth."},{"key":"ref_168","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1097\/ALN.0000000000003441","article-title":"Benefit and Risk Evaluation of Biased mu-Receptor Agonist Oliceridine versus Morphine","volume":"133","author":"Dahan","year":"2020","journal-title":"Anesthesiology"},{"key":"ref_169","doi-asserted-by":"crossref","first-page":"2495","DOI":"10.1126\/science.286.5449.2495","article-title":"Enhanced morphine analgesia in mice lacking beta-arrestin 2","volume":"286","author":"Bohn","year":"1999","journal-title":"Science"},{"key":"ref_170","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1124\/jpet.105.087254","article-title":"Morphine side effects in beta-arrestin 2 knockout mice","volume":"314","author":"Raehal","year":"2005","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"ref_171","doi-asserted-by":"crossref","first-page":"2822","DOI":"10.2174\/1568026620999201027224229","article-title":"The G Protein Signal-Biased Compound TRV130; Structures, Its Site of Action and Clinical Studies","volume":"20","author":"Miyano","year":"2020","journal-title":"Curr. Top. Med. Chem."},{"key":"ref_172","doi-asserted-by":"crossref","first-page":"8019","DOI":"10.1021\/jm4010829","article-title":"Structure-activity relationships and discovery of a G protein biased mu opioid receptor ligand, [(3-methoxythiophen-2-yl)methyl](2-[(9R)-9-(pyridin-2-yl)-6-oxaspiro-[4.5]decan-9-yl]ethyl)amine (TRV130), for the treatment of acute severe pain","volume":"56","author":"Chen","year":"2013","journal-title":"J. Med. Chem."},{"key":"ref_173","unstructured":"Oliceridine Briefing Document (2023, April 10). FDA Advisory Committee Meeting. 11 October 2018, Available online: https:\/\/www.fda.gov\/media\/121230\/download."},{"key":"ref_174","unstructured":"Food and Drug Administration (FDA) (2023, March 26). Highlights of Prescribing Information\u2014Olinvyk (Oliceridine), Available online: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2021\/210730s001lbl.pdf."},{"key":"ref_175","doi-asserted-by":"crossref","first-page":"1414","DOI":"10.1213\/ANE.0000000000003662","article-title":"Pharmacological Characters of Oliceridine, a mu-Opioid Receptor G-Protein-Biased Ligand in Mice","volume":"129","author":"Liang","year":"2019","journal-title":"Anesth. Analg."},{"key":"ref_176","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1177\/0269881116689257","article-title":"Effects of acute and repeated treatment with the biased mu opioid receptor agonist TRV130 (oliceridine) on measures of antinociception, gastrointestinal function, and abuse liability in rodents","volume":"31","author":"Altarifi","year":"2017","journal-title":"J. Psychopharmacol."},{"key":"ref_177","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1002\/jcph.207","article-title":"First clinical experience with TRV130: Pharmacokinetics and pharmacodynamics in healthy volunteers","volume":"54","author":"Soergel","year":"2014","journal-title":"J. Clin. Pharmacol."},{"key":"ref_178","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1097\/ALN.0000000000004473","article-title":"Respiratory Effects of Biased Ligand Oliceridine in Older Volunteers: A Pharmacokinetic-Pharmacodynamic Comparison with Morphine","volume":"138","author":"Simons","year":"2023","journal-title":"Anesthesiology"},{"key":"ref_179","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1002\/cpdd.750","article-title":"The Influence of Renal or Hepatic Impairment on the Pharmacokinetics, Safety, and Tolerability of Oliceridine","volume":"9","author":"Nafziger","year":"2020","journal-title":"Clin. Pharmacol. Drug Dev."},{"key":"ref_180","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1097\/j.pain.0000000000000363","article-title":"A randomized, phase 2 study investigating TRV130, a biased ligand of the mu-opioid receptor, for the intravenous treatment of acute pain","volume":"157","author":"Viscusi","year":"2016","journal-title":"Pain"},{"key":"ref_181","doi-asserted-by":"crossref","first-page":"2413","DOI":"10.2147\/JPR.S137952","article-title":"A randomized, Phase IIb study investigating oliceridine (TRV130), a novel micro-receptor G-protein pathway selective (mu-GPS) modulator, for the management of moderate to severe acute pain following abdominoplasty","volume":"10","author":"Singla","year":"2017","journal-title":"J. Pain Res."},{"key":"ref_182","doi-asserted-by":"crossref","first-page":"927","DOI":"10.2147\/JPR.S171013","article-title":"APOLLO-1: A randomized placebo and active-controlled phase III study investigating oliceridine (TRV130), a G protein-biased ligand at the micro-opioid receptor, for management of moderate-to-severe acute pain following bunionectomy","volume":"12","author":"Viscusi","year":"2019","journal-title":"J. Pain Res."},{"key":"ref_183","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1111\/papr.12801","article-title":"APOLLO-2: A Randomized, Placebo and Active-Controlled Phase III Study Investigating Oliceridine (TRV130), a G Protein-Biased Ligand at the mu-Opioid Receptor, for Management of Moderate to Severe Acute Pain Following Abdominoplasty","volume":"19","author":"Singla","year":"2019","journal-title":"Pain Pract."},{"key":"ref_184","doi-asserted-by":"crossref","first-page":"3113","DOI":"10.2147\/JPR.S217563","article-title":"ATHENA: A Phase 3, Open-Label Study Of The Safety And Effectiveness Of Oliceridine (TRV130), A G-Protein Selective Agonist At The micro-Opioid Receptor, In Patients With Moderate To Severe Acute Pain Requiring Parenteral Opioid Therapy","volume":"12","author":"Bergese","year":"2019","journal-title":"J. Pain Res."},{"key":"ref_185","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1007\/s40122-020-00232-x","article-title":"Low Incidence of Opioid-Induced Respiratory Depression Observed with Oliceridine Regardless of Age or Body Mass Index: Exploratory Analysis from a Phase 3 Open-Label Trial in Postsurgical Pain","volume":"10","author":"Brzezinski","year":"2021","journal-title":"Pain Ther."},{"key":"ref_186","doi-asserted-by":"crossref","first-page":"4361","DOI":"10.1016\/j.cell.2022.09.041","article-title":"Molecular recognition of morphine and fentanyl by the human mu-opioid receptor","volume":"185","author":"Zhuang","year":"2022","journal-title":"Cell"},{"key":"ref_187","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.1038\/s41594-022-00859-8","article-title":"Structure determination of inactive-state GPCRs with a universal nanobody","volume":"29","author":"Robertson","year":"2022","journal-title":"Nat. Struct. Mol. Biol."}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/24\/13\/10888\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T20:03:17Z","timestamp":1760126597000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/24\/13\/10888"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6,29]]},"references-count":187,"journal-issue":{"issue":"13","published-online":{"date-parts":[[2023,7]]}},"alternative-id":["ijms241310888"],"URL":"https:\/\/doi.org\/10.3390\/ijms241310888","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,6,29]]}}}